Graham George Adam Inglis

This inventor holds 9 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 2 EPO patents. Top assignees: Glaxo Group Limited, Glaxosmithkline Intellectual Property Development Limited, Glaxo Wellcome Inc.. Active years: 2001-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Graham George Adam Inglis. Retrieved from https://idiyas.com/inventor/graham-george-adam-inglis

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 2)

% Patents Active = 77.8

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 7.1

ph-index = 2

Forward Citations = 31(Granted Patents)

Location History:

Hertfordshire, GB (2007)
Stevenage, GB (2001 - 2022)

Company Filing History:

Glaxosmithkline Intellectual Property Development Limited

Biota Scientific Management Pty Ltd

patents

Years Active: 2001-2022

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11254671 - Chemical compounds (2022-02-22),

2. 10793559 - Chemical compounds (2020-10-06),

3. 10457674 - Chemical compounds (2019-10-29),

4. 8247377 - Non-steroidal glucocorticoid inhibitors and their use in treating inflammation, allergy and auto-immune conditions (2012-08-21),

5. 8093281 - Indazoles as glucocorticoid receptor ligands (2012-01-10),

6. 7288564 - Indole derivatives (2007-10-30),

7. 7230114 - Intermediates for preparing neuraminidase inhibitor conjugates (2007-06-12),

8. 6228853 - Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase (2001-05-08),

9. 6177425 - Pyrrolopyrrolone derivatives (2001-01-23),

Title: Graham George Adam Inglis: Pioneering Innovations in Pharmacology

Introduction:

Graham George Adam Inglis, a visionary inventor hailing from Stevenage, Great Britain, stands as a beacon of innovation in the realm of pharmacology. His relentless pursuit of scientific advancement has led to groundbreaking inventions that have reshaped the field and brought hope to those suffering from debilitating diseases.

Latest Patents:

Inglis holds a total of 9 patents, with his latest inventions focusing on chemical compounds with mTOR kinase inhibitor activity. These compounds, along with their pharmaceutical compositions, have shown promising potential in the treatment of diseases such as idiopathic pulmonary fibrosis. The novel compounds also act as inhibitors of PI3-kinase activity, further demonstrating Inglis's versatility and ingenuity in pharmacological research.

Career Highlights:

Throughout his illustrious career, Inglis has made significant contributions to the pharmaceutical industry. He has been associated with esteemed companies such as Glaxo Group Limited and GlaxoSmithKline Intellectual Property Development Limited, where his innovative spirit and dedication to scientific excellence have been instrumental in driving forward drug discovery and development.

Collaborations:

Inglis has collaborated with esteemed professionals in the field, including Simon John Fawcett MacDonald and Anthony William James Cooper. Together, they have combined their expertise to tackle complex challenges in pharmacology, fostering a culture of innovation and collaboration that has yielded remarkable results.

Conclusion:

In conclusion, Graham George Adam Inglis's pioneering work in pharmacology epitomizes the transformative power of innovation. His visionary inventions not only push the boundaries of scientific knowledge but also offer hope for a brighter, healthier future. Inglis's impact serves as a testament to the profound influence that one individual can have on the world through their inventive creations.

Profile summary based on public USPTO records.